{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T14:26:37Z","timestamp":1777991197331,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T00:00:00Z","timestamp":1614124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-021-01931-0","type":"journal-article","created":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T15:16:10Z","timestamp":1614179770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Preformulation Characterization of Griffithsin, a Biopharmaceutical Candidate for HIV Prevention"],"prefix":"10.1208","volume":"22","author":[{"given":"Lindsay F.","family":"Kramzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystal T.","family":"Hamorsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip W.","family":"Graebing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua L.","family":"Fuqua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Matoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda B.","family":"Lasnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard J.","family":"Moncla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth E.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa C.","family":"Rohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,24]]},"reference":[{"key":"1931_CR1","unstructured":"UNAIDS. Fact Sheet - Global AIDS Update 2019 2019 [Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"issue":"10","key":"1931_CR2","doi-asserted-by":"publisher","first-page":"9345","DOI":"10.1074\/jbc.M411122200","volume":"280","author":"T Mori","year":"2005","unstructured":"Mori T, O'Keefe BR, Sowder RC 2nd, Bringans S, Gardella R, Berg S, et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem. 2005;280(10):9345\u201353.","journal-title":"J Biol Chem."},{"issue":"15","key":"1931_CR3","doi-asserted-by":"publisher","first-page":"6099","DOI":"10.1073\/pnas.0901506106","volume":"106","author":"BR O'Keefe","year":"2009","unstructured":"O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A. 2009;106(15):6099\u2013104.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"1931_CR4","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1128\/AAC.01407-13","volume":"58","author":"C Barton","year":"2014","unstructured":"Barton C, Kouokam JC, Lasnik AB, Foreman O, Cambon A, Brock G, et al. Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrob Agents Chemother. 2014;58(1):120\u20137.","journal-title":"Antimicrob Agents Chemother."},{"issue":"1","key":"1931_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2010.03.021","volume":"402","author":"KB Alexandre","year":"2010","unstructured":"Alexandre KB, Gray ES, Lambson BE, Moore PL, Choge IA, Mlisana K, et al. Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin. Cyanovirin-N and Scytovirin. Virology. 2010;402(1):187\u201396.","journal-title":"Cyanovirin-N and Scytovirin. Virology."},{"issue":"11","key":"1931_CR6","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1089\/aid.2012.0026","volume":"28","author":"G F\u00e9rir","year":"2012","unstructured":"F\u00e9rir G, Huskens D, Palmer KE, Boudreaux DM, Swanson MD, Markovitz DM, et al. Combinations of griffithsin with other carbohydrate-binding agents demonstrate superior activity against HIV type 1, HIV type 2, and selected carbohydrate-binding agent-resistant HIV Type 1 strains. AIDS Res Hum Retroviruses. 2012;28(11):1513\u201323.","journal-title":"AIDS Res Hum Retroviruses."},{"key":"1931_CR7","doi-asserted-by":"crossref","unstructured":"Barton C, Kouokam JC, Hurst H, Palmer KE. Pharmacokinetics of the antiviral lectin griffithsin administered by different routes indicates multiple potential uses. Viruses. 2016;8(12).","DOI":"10.3390\/v8120331"},{"issue":"12","key":"1931_CR8","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.1128\/AAC.01816-15","volume":"59","author":"K Levendosky","year":"2015","unstructured":"Levendosky K, Mizenina O, Martinelli E, Jean-Pierre N, Kizima L, Rodriguez A, et al. Griffithsin and carrageenan combination to target herpes simplex virus 2 and human papillomavirus. Antimicrob Agents Chemother. 2015;59(12):7290\u20138.","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"1931_CR9","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.1128\/JVI.00012-13","volume":"87","author":"B Nixon","year":"2013","unstructured":"Nixon B, Stefanidou M, Mesquita PMM, Fakioglu E, Segarra T, Rohan L, et al. Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. Journal of Virology. 2013;87(11):6257\u201369.","journal-title":"Journal of Virology."},{"key":"1931_CR10","volume-title":"Krumpe LRH","author":"MK Lo","year":"2020","unstructured":"Lo MK, Spengler JR. Krumpe LRH. Chattopadhyay A, Harmon JR, et al. Griffithsin inhibits Nipah virus entry and fusion and can protect Syrian golden hamsters from lethal Nipah virus challenge. J Infect Dis: Welch SR; 2020."},{"issue":"11","key":"1931_CR11","doi-asserted-by":"publisher","first-page":"5159","DOI":"10.1128\/AAC.00633-11","volume":"55","author":"P Meuleman","year":"2011","unstructured":"Meuleman P, Albecka A, Belouzard S, Vercauteren K, Verhoye L, Wychowski C, et al. Griffithsin has antiviral activity against hepatitis C virus. Antimicrobial agents and chemotherapy. 2011;55(11):5159\u201367.","journal-title":"Antimicrobial agents and chemotherapy."},{"issue":"5","key":"1931_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064449","volume":"8","author":"Y Takebe","year":"2013","unstructured":"Takebe Y, Saucedo CJ, Lund G, Uenishi R, Hase S, Tsuchiura T, et al. Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One. 2013;8(5):e64449.","journal-title":"PLoS One."},{"issue":"2","key":"1931_CR13","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00705-012-1489-2","volume":"158","author":"HZA Ishag","year":"2013","unstructured":"Ishag HZA, Li C, Huang L. Sun M-x, Wang F, Ni B, et al. Griffithsin inhibits Japanese encephalitis virus infection in vitro and in vivo. Archives of Virology. 2013;158(2):349\u201358.","journal-title":"Archives of Virology."},{"key":"1931_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.virusres.2016.01.016","volume":"215","author":"HZA Ishag","year":"2016","unstructured":"Ishag HZA, Li C, Wang F, Mao X. Griffithsin binds to the glycosylated proteins (E and prM) of Japanese encephalitis virus and inhibit its infection. Virus Research. 2016;215:50\u20134.","journal-title":"Virus Research."},{"issue":"5","key":"1931_CR15","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1128\/JVI.02322-09","volume":"84","author":"BR O'Keefe","year":"2010","unstructured":"O'Keefe BR, Giomarelli B, Barnard DL, Shenoy SR, Chan PK, McMahon JB, et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol. 2010;84(5):2511\u201321.","journal-title":"J Virol."},{"key":"1931_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2016.07.011","volume":"133","author":"JK Millet","year":"2016","unstructured":"Millet JK, Seron K, Labitt RN, Danneels A, Palmer KE, Whittaker GR, et al. Middle East respiratory syndrome coronavirus infection is inhibited by griffithsin. Antiviral Res. 2016;133:1\u20138.","journal-title":"Antiviral Res."},{"key":"1931_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.antiviral.2017.03.007","volume":"142","author":"CA Mitchell","year":"2017","unstructured":"Mitchell CA, Ramessar K, O'Keefe BR. Antiviral lectins: selective inhibitors of viral entry. Antiviral research. 2017;142:37\u201354.","journal-title":"Antiviral research."},{"key":"1931_CR18","doi-asserted-by":"crossref","unstructured":"Lusvarghi S, Bewley CA. Griffithsin: an antiviral lectin with outstanding therapeutic potential. Viruses. 2016;8(10).","DOI":"10.3390\/v8100296"},{"issue":"10","key":"1931_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3390\/md17100567","volume":"17","author":"C Lee","year":"2019","unstructured":"Lee C. Griffithsin, a highly potent broad-spectrum antiviral lectin from red algae: from discovery to clinical application. Mar Drugs. 2019;17(10):567.","journal-title":"Mar Drugs."},{"issue":"4-5","key":"1931_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1600-0684.2007.00242.x","volume":"36","author":"P Emau","year":"2007","unstructured":"Emau P, Tian B, O'Keefe BR, Mori T, McMahon JB, Palmer KE, et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. Journal of medical primatology. 2007;36(4-5):244\u201353.","journal-title":"Journal of medical primatology."},{"issue":"3","key":"1931_CR21","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/prot.21336","volume":"67","author":"NE Ziolkowska","year":"2007","unstructured":"Ziolkowska NE, Shenoy SR, O'Keefe BR, McMahon JB, Palmer KE, Dwek RA, et al. Crystallographic, thermodynamic, and molecular modeling studies of the mode of binding of oligosaccharides to the potent antiviral protein griffithsin. Proteins. 2007;67(3):661\u201370.","journal-title":"Proteins."},{"issue":"7","key":"1931_CR22","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1110\/ps.072889407","volume":"16","author":"NE Ziolkowska","year":"2007","unstructured":"Ziolkowska NE, Shenoy SR, O'Keefe BR, Wlodawer A. Crystallographic studies of the complexes of antiviral protein griffithsin with glucose and N-acetylglucosamine. Protein Sci. 2007;16(7):1485\u20139.","journal-title":"Protein Sci."},{"key":"1931_CR23","unstructured":"Population Council [Available from: https:\/\/www.popcouncil.org\/."},{"issue":"1","key":"1931_CR24","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1038\/s41467-018-06349-0","volume":"9","author":"N Derby","year":"2018","unstructured":"Derby N, Lal M, Aravantinou M, Kizima L, Barnable P, Rodriguez A, et al. Griffithsin carrageenan fast dissolving inserts prevent SHIV HSV-2 and HPV infections in vivo. Nat Commun. 2018;9(1):3881.","journal-title":"Nat Commun."},{"issue":"1","key":"1931_CR25","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1038\/s41598-018-26313-8","volume":"8","author":"L Girard","year":"2018","unstructured":"Girard L, Birse K, Holm JB, Gajer P, Humphrys MS, Garber D, et al. Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates. Sci Rep. 2018;8(1):8059.","journal-title":"Sci Rep."},{"key":"1931_CR26","doi-asserted-by":"crossref","unstructured":"Grooms TN, Vuong HR, Tyo KM, Malik DA, Sims LB, Whittington CP, Palmer KE, Matoba N, Steinbach-Rankins JM Griffithsin-modified electrospun fibers as a delivery scaffold to prevent HIV infection. Antimicrob Agents Chemother. 2016;60(11):6518-6531, Griffithsin-Modified Electrospun Fibers as a Delivery Scaffold To Prevent HIV Infection.","DOI":"10.1128\/AAC.00956-16"},{"issue":"10","key":"1931_CR27","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1016\/j.xphs.2018.06.002","volume":"107","author":"M Lal","year":"2018","unstructured":"Lal M, Lai M, Ugaonkar S, Wesenberg A, Kizima L, Rodriguez A, et al. Development of a vaginal fast-dissolving insert combining griffithsin and carrageenan for potential use against sexually transmitted infections. J Pharm Sci. 2018;107(10):2601\u201310.","journal-title":"J Pharm Sci."},{"issue":"11","key":"1931_CR28","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.1128\/JVI.00012-13","volume":"87","author":"B Nixon","year":"2013","unstructured":"Nixon B, Stefanidou M, Mesquita PM, Fakioglu E, Segarra T, Rohan L, et al. Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. J Virol. 2013;87(11):6257\u201369.","journal-title":"J Virol."},{"key":"1931_CR29","volume-title":"Kollipara P","author":"KM Tyo","year":"2018","unstructured":"Tyo KM, Duan J. Kollipara P. Lee D, Palmer KE, et al. pH-responsive delivery of griffithsin from electrospun fibers. Eur J Pharm Biopharm: Dela Cerna MVC; 2018."},{"key":"1931_CR30","doi-asserted-by":"crossref","unstructured":"Vuong HR, Tyo KM, Steinbach-Rankins JM. Fabrication and characterization of griffithsin-modified fiber scaffolds for prevention of sexually transmitted infections. J Vis Exp. 2017;128.","DOI":"10.3791\/56492"},{"issue":"4","key":"1931_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/00003081-197412000-00003","volume":"17","author":"M Lemert","year":"1974","unstructured":"Lemert M, Mastroianni L Jr. Cervical factors in infertility. Clin Obstet Gynecol. 1974;17(4):29\u201343.","journal-title":"Clin Obstet Gynecol."},{"issue":"6","key":"1931_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/0002-9378(77)90644-5","volume":"129","author":"GF Schumacher","year":"1977","unstructured":"Schumacher GF, Kim MH, Hosseinian AH, Dupon C. Immunoglobulins, proteinase inhibitors, albumin, and lysozyme in human cervical mucus. I. Communication: hormonal profiles and cervical mucus changes--methods and results. Am J Obstet Gynecol. 1977;129(6):629\u201336.","journal-title":"Am J Obstet Gynecol."},{"issue":"3","key":"1931_CR33","first-page":"347","volume":"48","author":"KS Moghissi","year":"1976","unstructured":"Moghissi KS, Syner FN, Borin B. Cyclic changes of cervical mucus enzymes related to the time of ovulation II. Amino peptidase and esterase. Obstet Gynecol. 1976;48(3):347\u201350.","journal-title":"Obstet Gynecol."},{"key":"1931_CR34","doi-asserted-by":"crossref","unstructured":"Moncla BJ, Chappell C, Mahal LK, Debo BM, Meyn L, Hillier S. Impact of bacterial vaginosis as assessed by Nugent score and hormonal status on glycosidases and lectin binding in cervicovaginal lavage samples. PLoS One. 2015;accepted; PONE-D-15-01714.","DOI":"10.1371\/journal.pone.0127091"},{"issue":"3","key":"1931_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1128\/jcm.30.3.663-666.1992","volume":"30","author":"AM Briselden","year":"1992","unstructured":"Briselden AM, Moncla BJ, Stevens CE, Hillier SL. Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. J Clin Microbiol. 1992;30(3):663\u20136.","journal-title":"J Clin Microbiol."},{"issue":"10","key":"1931_CR36","doi-asserted-by":"publisher","first-page":"5027","DOI":"10.1128\/IAI.67.10.5027-5032.1999","volume":"67","author":"N Rajan","year":"1999","unstructured":"Rajan N, Cao Q, Anderson BE, Pruden DL, Sensibar J, Duncan JL, et al. Roles of glycoproteins and oligosaccharides found in human vaginal fluid in bacterial adherence. Infect Immun. 1999;67(10):5027\u201332.","journal-title":"Infect Immun."},{"issue":"3","key":"1931_CR37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1067\/mob.2002.125280","volume":"187","author":"EV Valore","year":"2002","unstructured":"Valore EV, Park CH, Igreti SL, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol. 2002;187(3):561\u20138.","journal-title":"Am J Obstet Gynecol."},{"issue":"2","key":"1931_CR38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","volume":"59","author":"DH Owen","year":"1999","unstructured":"Owen DH, Katz DF. A vaginal fluid simulant. Contraception. 1999;59(2):91\u20135.","journal-title":"Contraception."},{"issue":"2","key":"1931_CR39","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.mimet.2011.12.013","volume":"88","author":"BJ Moncla","year":"2012","unstructured":"Moncla BJ, Pryke K, Rohan LC, Yang H. Testing of viscous anti-HIV microbicides using Lactobacillus. J Microbiol Methods. 2012;88(2):292\u20136.","journal-title":"J Microbiol Methods."},{"issue":"8","key":"1931_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022635","volume":"6","author":"JC Kouokam","year":"2011","unstructured":"Kouokam JC, Huskens D, Schols D, Johannemann A, Riedell SK, Walter W, et al. Investigation of griffithsin's interactions with human cells confirms its outstanding safety and efficacy profile as a microbicide candidate. PLoS One. 2011;6(8):e22635.","journal-title":"PLoS One."},{"issue":"3","key":"1931_CR41","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/jps.22826","volume":"101","author":"L Zhang","year":"2012","unstructured":"Zhang L, Tan H, Fesinmeyer RM, Li C, Catrone D, Le D, et al. Antibody solubility behavior in monovalent salt solutions reveals specific anion effects at low ionic strength. J Pharm Sci. 2012;101(3):965\u201377.","journal-title":"J Pharm Sci."},{"issue":"6","key":"1931_CR42","doi-asserted-by":"publisher","first-page":"404","DOI":"10.4236\/abb.2011.26059","volume":"2","author":"BJ Moncla","year":"2011","unstructured":"Moncla BJ, Pryke K, Rohan LC, Graebing PW. Degradation of naturally occurring and engineered antimicrobial peptides by proteases. Adv Biosci Biotechnol. 2011;2(6):404\u20138.","journal-title":"Adv Biosci Biotechnol."},{"key":"1931_CR43","doi-asserted-by":"crossref","unstructured":"Wang L, Koppolu S, Chappell C, Moncla BJ, Hillier SL, Mahal LK. Studying the effects of reproductive hormones and bacterial vaginosis on the glycome of lavage samples from the cervicovaginal cavity. PLoS One. 2015;accepted; PONE-D-15-01897.","DOI":"10.1371\/journal.pone.0127021"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-01931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-021-01931-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-021-01931-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:44:18Z","timestamp":1744184658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-021-01931-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,24]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["1931"],"URL":"https:\/\/doi.org\/10.1208\/s12249-021-01931-0","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,24]]},"assertion":[{"value":"13 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The contents of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the NIAID.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}],"article-number":"83"}}